Submission of NDA to FDA completed for PF 03084014 in desmoid tumors
SpringWorks Therapeutics announced that the Company has completed the submission of a New Drug Application (NDA) to the FDA for PF 03084014 (nirogacestat), an investigational gamma secretase inhibitor, for the treatment of adults with desmoid tumors
The NDA submission is being reviewed under the FDA’s Real-Time Oncology Review (RTOR) program and includes data from the Phase III DeFi trial, a global, randomized, double-blind, placebo-controlled trial in adult patients with desmoid tumors. The FDA previously granted Fast Track and Breakthrough Therapy designations to nirogacestat for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis. Nirogacestat has also received Orphan Drug designation from the FDA for the treatment of desmoid tumors and from the European Commission for the treatment of soft tissue sarcoma.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins